CapsoVision, Inc.
CVCapsoVision, Inc. in brief
CapsoVision, Inc. is a listed company in the Medical Devices industry, based in Saratoga, California, USA. Its market value was $372 M on 30 October 2026, which makes it the 13,850th largest listed company in the world and the 2,722nd largest in the USA on this site. In the year to December 2025 it had sales of $14 M and a net loss of $25 M. It employs about 99 people. Its shares trade under the symbol CV (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About CapsoVision, Inc.
We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.
Currently, our GI-tract capsule endoscopy solution comprises our single-use CapsoCam capsule and the associated software, CapsoCloud and CapsoView. The CapsoCam capsule, with its panoramic view, acquires and stores video images in onboard memory while moving through the GI tract and the software component allows healthcare providers to view the video retrieved from the capsule by either streaming it from the cloud, where it is securely stored, anywhere at their convenience using our CapsoCloud software or downloading data from the capsule themselves and reviewing it in our CapsoView software. Our first U.S. Food and Drug Administration cleared capsule endoscopy is our small bowel capsule (the current generation of which we refer to as CapsoCam Plus), for which we received a CE Mark in 2011 and began commercial sales in Europe in 2012, subsequent to which we received 510(k) clearance in 2016 and began commercial sales in the U.S. in 2017. CapsoCam Plus is classified as a Class II device and is used to visualize the small bowel mucosa to detect abnormalities of the small bowel in adults and children aged 2 years and above. As of December 31, 2025, our CapsoCam Plus has been used in more than 161,000 patients. For the years ended December 31, 2025 and 2024, we generated approximately $13.6 million and $11.8 million, respectively, in revenue from sales of CapsoCam Plus, an increase of approximately 15% over the prior year. Our revenue has increased in each year since we began U.S.
From the company's annual report filed with the US SEC: read the report
CapsoVision, Inc. timeline
- 2006
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2025
- 🔔· approximateInitial public offering on Nasdaq
Events of CapsoVision, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,816 (Aug 2026) · #2,733 (Oct 2026) · #2,726 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 26.7×
- Price / book
- 28.1×
- Free cash flow yield
- -6.2%
- Net margin (TTM)
- -210.3%
- Operating margin
- -188.3%
- Return on equity
- -220.6%
- Liabilities / assets
- 27.0%
- Revenue growth
- +15.2%
- R&D / revenue
- 135.1%
- Revenue per employee
- $137 K
- Profit per employee
- $-256 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $14M | +15.2% | $-26M | $-25M | -186.9% |
| Dec 2024 | $12M | — | $-20M | $-20M | -169.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-23M | $0M | $-23M | $-1.03 | — |
| Dec 2024 | $-20M | $0M | $-20M | $-9.85 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $4M (+0.8% on a year earlier), net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Sep 28, 20268-KCurrent reportOther events
- Sep 18, 20268-KCurrent reportMaterial agreement
- Aug 18, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportMaterial agreement · Results of operations
- Jul 2, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Jun 12, 20268-KCurrent reportShareholder vote
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations
- Apr 28, 2026DEF 14AProxy statement
Official filings of CapsoVision, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $14 M
- Operating income
- $-26 M
- Net income
- $-25 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $18 M
- Total liabilities
- $5 M
- Total equity
- $13 M
As of December-2025
Top 50 institutional investors in CapsoVision, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2,327,875 | +431,787 (+22.77%) | 4.34% | $15 M | Nov 13, 2026 |
| 2 | Vanguard Capital Management LLC | 1,341,834 | +283,366 (+26.77%) | 2.50% | $9 M | Nov 13, 2026 |
| 3 | Geode Capital Management, LLC | 852,669 | +274,187 (+47.40%) | 1.59% | $6 M | Nov 6, 2026 |
| 4 | State Street Corp | 487,066 | +76,825 (+18.73%) | 0.91% | $3 M | Nov 12, 2026 |
| 5 | Vanguard Fiduciary Trust Co | 260,901 | +157,271 (+151.76%) | 0.49% | $2 M | Nov 13, 2026 |
| 6 | Vanguard Portfolio Management LLC | 244,546 | +4,121 (+1.71%) | 0.46% | $2 M | Nov 13, 2026 |
| 7 | UBS Group AG | 132,651 | +125,354 (+1717.88%) | 0.25% | $1 M | Nov 10, 2026 |
| 8 | Charles Schwab Investment Management Inc | 85,040 | +5,680 (+7.16%) | 0.16% | $1 M | Nov 16, 2026 |
| 9 | Bank of New York Mellon Corp | 75,387 | +366 (+0.49%) | 0.14% | $0 M | Nov 5, 2026 |
| 10 | Goldman Sachs Group Inc | 65,022 | +46,395 (+249.07%) | 0.12% | $0 M | Nov 16, 2026 |
| 11 | Nuveen, LLC | 46,080 | +69 (+0.15%) | 0.09% | $0 M | Nov 10, 2026 |
| 12 | Bank Of America Corp /de/ | 39,470 | +14,001 (+54.97%) | 0.07% | $0 M | Nov 16, 2026 |
| 13 | Rhumbline Advisers | 37,939 | +15,970 (+72.69%) | 0.07% | $0 M | Nov 10, 2026 |
| 14 | Deutsche Bank AG\ | 30,451 | -4,249 (-12.24%) | 0.06% | $0 M | Nov 6, 2026 |
| 15 | Price T Rowe Associates Inc /MD/ | 29,026 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 16 | Morgan Stanley | 23,917 | +5,194 (+27.74%) | 0.04% | $0 M | Nov 13, 2026 |
| 17 | Barclays PLC | 19,796 | +8,000 (+67.82%) | 0.04% | $0 M | Nov 6, 2026 |
| 18 | Invesco Ltd. | 19,096 | +269 (+1.43%) | 0.04% | $0 M | Nov 12, 2026 |
| 19 | Jpmorgan Chase & Co | 17,227 | +2,661 (+18.27%) | 0.03% | $0 M | Nov 12, 2026 |
| 20 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 16,918 | +854 (+5.32%) | 0.03% | $0 M | Nov 16, 2026 |
| 21 | MetLife Investment Management, LLC | 13,092 | -8,022 (-37.99%) | 0.02% | $0 M | Nov 16, 2026 |
| 22 | Russell Investments Group, Ltd. | 12,419 | -2,030 (-14.05%) | 0.02% | $0 M | Nov 6, 2026 |
| 23 | Vanguard Global Advisers, LLC | 11,317 | +8,777 (+345.55%) | 0.02% | $0 M | Nov 13, 2026 |
| 24 | Wells Fargo & Company/mn | 10,600 | -21,220 (-66.69%) | 0.02% | $0 M | Nov 16, 2026 |
| 25 | BNP Paribas Financial Markets | 8,797 | +3,223 (+57.82%) | 0.02% | $0 M | Nov 12, 2026 |
Show all 50: investors 26 to 50
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Police & Firemen's Retirement System of New Jersey | 7,185 | -6,092 (-45.88%) | 0.01% | $0 M | Nov 9, 2026 |
| 27 | New York State Common Retirement Fund | 7,114 | 0 (0.00%) | 0.01% | $0 M | Nov 17, 2026 |
| 28 | Legal & General Group Plc | 3,397 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 29 | Tower Research Capital LLC (TRC) | 2,564 | +82 (+3.30%) | 0.00% | $0 M | Nov 16, 2026 |
| 30 | Ameritas Investment Partners, Inc. | 2,279 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 31 | Royal Bank Of Canada | 2,209 | +643 (+41.06%) | 0.00% | $0 M | Nov 16, 2026 |
| 32 | Citigroup Inc | 1,730 | -14,654 (-89.44%) | 0.00% | $0 M | Nov 4, 2026 |
| 33 | TD Waterhouse Canada Inc. | 1,500 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 34 | Sterling Capital Management LLC | 1,144 | +1,022 (+837.70%) | 0.00% | $0 M | Oct 22, 2026 |
| 35 | FMR LLC | 1,126 | -3,074 (-73.19%) | 0.00% | $0 M | Nov 10, 2026 |
| 36 | California State Teachers Retirement System | 391 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 37 | PNC Financial Services Group, Inc. | 220 | New | 0.00% | $0 M | Nov 6, 2026 |
| 38 | GAMMA Investing LLC | 174 | +39 (+28.89%) | 0.00% | $0 M | Oct 8, 2026 |
| 39 | Physician Wealth Advisors, Inc. | 83 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 40 | Fortitude Family Office, LLC | 83 | New | 0.00% | $0 M | Oct 14, 2026 |
| 41 | Allworth Financial LP | 66 | +51 (+340.00%) | 0.00% | $0 M | Nov 17, 2026 |
| 42 | Arax Advisory Partners | 58 | -21 (-26.58%) | 0.00% | $0 M | Nov 12, 2026 |
| 43 | Root Financial Partners, LLC | 47 | New | 0.00% | $0 M | Oct 21, 2026 |
| 44 | Osaic Holdings, Inc. | 22 | -2 (-8.33%) | 0.00% | $0 M | Nov 12, 2026 |
| 45 | Caitong International Asset Management Co., Ltd | 12 | New | 0.00% | $0 M | Oct 29, 2026 |
| 46 | Transamerica Financial Advisors, LLC | 11 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 47 | Farther Finance Advisors, LLC | 10 | -3 (-23.08%) | 0.00% | $0 M | Oct 8, 2026 |
| 48 | EverSource Wealth Advisors, LLC | 5 | 0 (0.00%) | 0.00% | $0 M | Nov 4, 2026 |
| 49 | Rothschild Investment LLC | 1 | -3 (-75.00%) | 0.00% | $0 M | Nov 10, 2026 |
| 50 | SJS Investment Consulting Inc. | 1 | New | 0.00% | $0 M | Oct 26, 2026 |
Mutual funds holding CapsoVision, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 925,200 | $7 M | 1.7% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 825,385 | $6 M | 1.5% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 381,157 | $3 M | 0.71% | <0.01% | +38% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 315,596 | $2 M | 0.59% | 0.02% | +112% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 142,359 | $1 M | 0.27% | <0.01% | +412% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 114,619 | $1 M | 0.21% | 0.06% | +63% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 100,983 | $1 M | 0.19% | <0.01% | +55% | Jun 30, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 85,030 | $1 M | 0.16% | <0.01% | +39% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 62,155 | $0 M | 0.12% | <0.01% | +585% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 46,011 | $0 M | 0.09% | <0.01% | +39% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 36,706 | $0 M | 0.07% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 32,592 | $0 M | 0.06% | 0.02% | +126% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 30,790 | $0 M | 0.06% | <0.01% | +24% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 29,810 | $0 M | 0.06% | <0.01% | +1.8% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 25,800 | $0 M | 0.05% | <0.01% | +1073% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 18,030 | $0 M | 0.03% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 16,307 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 15,978 | $0 M | 0.03% | <0.01% | −18% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 17,618 | $0 M | 0.03% | <0.01% | +406% | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 16,675 | $0 M | 0.03% | <0.01% | +38% | Jul 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 11,929 | $0 M | 0.02% | <0.01% | +24% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 10,872 | $0 M | 0.02% | <0.01% | +55% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 11,520 | $0 M | 0.02% | <0.01% | +440% | May 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 9,461 | $0 M | 0.02% | <0.01% | −2.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 10,476 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 9,003 | $0 M | 0.02% | <0.01% | +64% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 8,879 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 7,651 | $0 M | 0.01% | 0.03% | +58% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 7,550 | $0 M | 0.01% | <0.01% | +46% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 6,927 | $0 M | 0.01% | <0.01% | +595% | May 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 5,499 | $0 M | 0.01% | <0.01% | +42% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 5,324 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 5,321 | $0 M | <0.01% | <0.01% | +82% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 6,064 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 5,109 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 5,071 | $0 M | <0.01% | <0.01% | +112% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 4,999 | $0 M | <0.01% | <0.01% | +56% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 4,525 | $0 M | <0.01% | <0.01% | +50% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 4,085 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 3,243 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 3,116 | $0 M | <0.01% | 0.02% | +94% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 3,384 | $0 M | <0.01% | <0.01% | +60% | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 2,771 | $0 M | <0.01% | <0.01% | +32% | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 3,183 | $0 M | <0.01% | <0.01% | −2.9% | Jul 31, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 2,524 | $0 M | <0.01% | <0.01% | +39% | Jun 30, 2026 |
| 🇺🇸 Invesco Russell 2000 Dynamic Multifactor ETFInvesco Capital Management LLC | 2,686 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 2,668 | $0 M | <0.01% | <0.01% | +72% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 2,279 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 2,493 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 1,400 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 1,400 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 1,312 | $0 M | <0.01% | <0.01% | +429% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 1,179 | $0 M | <0.01% | <0.01% | +186% | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,011 | $0 M | <0.01% | <0.01% | −41% | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,038 | $0 M | <0.01% | <0.01% | +193% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,025 | $0 M | <0.01% | <0.01% | +191% | May 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 829 | $0 M | <0.01% | <0.01% | +5.1% | Jun 30, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 662 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 662 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 107 | $0 M | <0.01% | <0.01% | +463% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 60 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at CapsoVision, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Eliyahou Harari10% owner | Buyindirect | +878,735 | $5.690 | $5.0 M | 1.40 M | Form 4 |
| filed | Eliyahou Harari10% owner | Buyindirect | +878,734 | $5.690 | $5.0 M | 878,734 | Form 4 |
| filed | Ching Hang Shen10% owner | Buyindirect · amended | +878,734 | $5.690 | $5.0 M | 7.28 M | Form 4/A |
| filed | Ching Hang Shen10% owner | Buyindirect | +878,734 | $5.690 | $5.0 M | 2.93 M | Form 4 |
| filed | Eliyahou Harari10% owner | Buyindirect | +61,068 | $6.730 | $411 K | 3.34 M | Form 4 |
| filed | Eliyahou Harari10% owner | Buyindirect | +81,300 | $6.090 | $495 K | 3.28 M | Form 4 |
| filed | Hui Ying KuoDirector | Option exercise | +2,022 | $7.580 | $15 K | 15,263 | Form 4 |
| filed | Julia S. GouwDirector | Option exercise | +2,022 | $7.580 | $15 K | 4,909 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: CapsoVision, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
IPO: priced at $5.00, raising $27.5M · IPO calendar
Trading halts
- 2025-12-19 20:55 UTC, code LUDP, resumed 21:00 UTC
- 2025-12-09 16:26 UTC, code LUDP, resumed 16:36 UTC
- 2025-07-02 19:57 UTC, code LUDP, resumed 20:00 UTC
Fails to deliver
- : 136 shares at $6.94
- : 5 shares at $7.06
- : 1,423 shares at $6.80
- : 43 shares at $6.64
- : 2,066 shares at $6.78
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
CapsoVision, Inc. scorecard#
Passes 3 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median28.1×Price to book 28.1× against Medical Devices's median of 2.5×.
- ✗Price to sales below its peers' median26.8×Price to sales 26.8× against Medical Devices's median of 2.4×.
- ✗Free cash flow yield above 5%-6.2%Free cash flow is -6.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- ✓Revenue grew in the newest year15.2%Revenue up 15.2% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.03 vs -9.85Diluted EPS -1.03 in fiscal 2025 against -9.85 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$25 MNet income -$25 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- ✗Operating margin above its peers' median-188.3%-188.3% against Medical Devices's median of -8.2% (86 companies).
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health2 of 2
- ✓Short-term assets cover short-term liabilities3.8×Current ratio 3.76 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
- ✓Altman Z-score outside the distress zone30.47Z-score 30.47 (safe zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from CapsoVision, Inc.'s statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -188.3% | -8.2% | |
| Net margin | -186.9% | -10.4% | |
| Revenue growth | 15.2% | 10.4% | |
| Free cash flow margin | -169.4% | -1.9% |
2of 8on the Piotroski tests of financial strength
- Net loss of $25 million.
- Free cash flow was negative: -$23 million.
CapsoVision, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 |
|---|---|---|---|
| Income statement | |||
| Revenue | 14+15.3%100% | 12—100% | |
| Cost of revenue | 6.4+18.6%47.1% | 5.4—45.8% | |
| Gross profit | 7.2+12.5%52.9% | 6.4—54.2% | |
| Research and development | 18+21.1%135% | 15—129% | |
| Selling and marketing | 7.5+8.1%55.6% | 7.0—59.3% | |
| General and administrative | 6.8+62.8%50.5% | 4.2—35.8% | |
| Operating expenses | 33+24.3%241% | 26—224% | |
| Operating income | −26—−188% | −20—−169% | |
| Other non-operating income (expense) | 0.2+650%1.7% | 0.0—0.3% | |
| Income before tax | −25—−187% | −20—−169% | |
| Income tax | 0.0+118%0.2% | 0.0—0.1% | |
| Net income attributable to shareholders | −25—−187% | −20—−169% | |
| Earnings per share, basic | -1.03—— | -9.85—— | |
| Earnings per share, diluted | -1.03—— | -9.85—— | |
| Shares, weighted average (basic) | 25+1116%— | 2.0—— | |
| Shares, weighted average (diluted) | 25+1116%— | 2.0—— | |
| Balance sheet | |||
| Receivables | 2.5+24.8%13.8% | 2.0—11.9% | |
| Inventory | 3.0+13.6%16.4% | 2.6—15.6% | |
| Other current assets | 0.4+72.3%2.5% | 0.3r0.3—1.5% | |
| Current assets | 17+12.3%91.8% | 15—88.4% | |
| Property, plant and equipment | 0.6−15.1%3.4% | 0.7—4.3% | |
| Right-of-use (leased) assets | 0.8−29.5%4.6% | 1.2—7.1% | |
| Total assets | 18+8.1%100% | 17—100% | |
| Accounts payable | 1.1+52.6%6.3% | 0.7—4.5% | |
| Current liabilities | 4.4+146%24.4% | 1.8—10.7% | |
| Lease liabilities (non-current) | 0.5−46.2%2.6% | 0.9—5.3% | |
| Total liabilities | 4.9+82.4%27.0% | 2.7—16.0% | |
| Retained earnings | −156—−857% | −130—−776% | |
| Shareholders' equity | 13—73.0% | −130—−771% | |
| Total liabilities and equity | 18+8.1%100% | 17—100% | |
| Shares outstanding | 47+2141%— | 2.1—— | |
| Cash-flow statement | |||
| Depreciation and amortization | 0.2+4.9%1.6% | 0.2—1.8% | |
| Share-based compensation | 0.8+429%6.1% | 0.2—1.3% | |
| Cash from operating activities | −23—−169% | −20—−171% | |
| Capital expenditure | −0.1—−0.7% | −0.2—−1.3% | |
| Cash from investing activities | −0.1—−0.7% | −0.2—−1.3% | |
| Cash from financing activities | 24+56.6%174% | 15—128% | |
| Report | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 14—100% | 3.6+0.8%100% | 3.6+9.9%100% | 2.8—100% | 3.9*—100% | 3.5—100% | 3.3—100% | |
| Cost of revenue | 7.0—50.3% | 1.8+11.1%50.6% | 1.8+17.8%48.6% | 1.5—52.4% | 2.0*—50.1% | 1.6—45.9% | 1.5—45.4% | |
| Gross profit | 6.9—49.7% | 1.8−7.8%49.4% | 1.9+3.3%51.4% | 1.3—47.6% | 2.0*—49.9% | 1.9—54.1% | 1.8—54.6% | |
| Research and development | 20—146% | 4.8−21.1%135% | 5.3+56.5%146% | 4.4—159% | 5.7*—146% | 6.1—172% | 3.4—102% | |
| Selling and marketing | 8.0—57.7% | 2.1+16.2%57.7% | 1.9+4.8%53.1% | 2.1—74.9% | 1.9*—49.7% | 1.8—50.1% | 1.8—55.7% | |
| General and administrative | 8.1—58.4% | 2.3+10.4%64.0% | 2.2+80.4%60.6% | 1.9—67.9% | 1.7*—44.6% | 2.1—58.5% | 1.2—36.9% | |
| Operating expenses | 36—262% | 9.1−7.9%256% | 9.5+46.3%259% | 8.4—302% | 9.4*—240% | 9.9—281% | 6.5—195% | |
| Operating income | −30—−212% | −7.4—−207% | −7.6—−208% | −7.1—−254% | −7.5*—−191% | −8.0—−227% | −4.7—−140% | |
| Other non-operating income (expense) | 0.3—2.1% | 0.0−54.1%1.3% | 0.1+281%2.7% | 0.1—2.1% | 0.1*—2.4% | 0.1—2.8% | 0.0—0.8% | |
| Income before tax | −29—−210% | −7.3—−206% | −7.5—−205% | −7.0—−252% | −7.4*—−188% | −7.9—−224% | −4.6—−140% | |
| Income tax | 0.0—0.2% | 0—0.0% | 0—0.0% | 0—0.0% | 0.0*—0.6% | 0—0.0% | 0—0.0% | |
| Net income attributable to shareholders | −29—−210% | −7.3—−206% | −7.5—−205% | −7.0—−252% | −7.4*—−189% | −7.9—−224% | −4.6—−140% | |
| Earnings per share, basic | — | -0.15—— | -0.15—— | -0.15—— | — | -0.17—— | -2.02—— | |
| Earnings per share, diluted | — | -0.15—— | -0.15—— | -0.15—— | — | -0.17—— | -2.02—— | |
| Shares, weighted average (basic) | 51—— | 51+9.4%— | 50+2079%— | 47—— | — | 46—— | 2.3—— | |
| Shares, weighted average (diluted) | 51—— | 51+9.4%— | 50+2079%— | 47—— | — | 46—— | 2.3—— | |
| Balance sheet | ||||||||
| Receivables | 2.5—7.5% | 2.5+31.3%7.5% | 2.3+22.2%12.2% | 1.9—7.4% | 2.5—13.8% | 1.9—7.3% | 1.9—19.4% | |
| Inventory | 4.7—14.5% | 4.7+48.9%14.5% | 4.7+54.6%25.3% | 3.5—13.5% | 3.0—16.4% | 3.2—12.4% | 3.0—31.9% | |
| Other current assets | 0.6—1.8% | 0.6+54.7%1.8% | 0.6+30.9%3.1% | 0.5—2.0% | 0.4—2.5% | 0.4—1.5% | 0.4—4.5% | |
| Current assets | 31—94.8% | 31+29.1%94.8% | 17+122%93.1% | 25—94.4% | 17—91.8% | 24—93.7% | 7.8—81.7% | |
| Property, plant and equipment | 0.5—1.6% | 0.5−20.6%1.6% | 0.6−17.7%3.0% | 0.6—2.4% | 0.6—3.4% | 0.6—2.5% | 0.7—7.2% | |
| Right-of-use (leased) assets | 0.7—2.3% | 0.7−20.1%2.3% | 0.7−36.4%3.5% | 0.7—2.9% | 0.8—4.6% | 0.9—3.6% | 1.0—10.7% | |
| Total assets | 33—100% | 33+27.6%100% | 19+94.5%100% | 26—100% | 18—100% | 26—100% | 9.5—100% | |
| Accounts payable | 1.1—3.4% | 1.1−18.1%3.4% | 0.5−58.9%2.6% | 1.4—5.2% | 1.1—6.3% | 1.3—5.2% | 1.2—12.1% | |
| Current liabilities | 6.1—18.7% | 6.1+32.1%18.7% | 5.2+22.2%27.8% | 5.4—20.7% | 4.4—24.4% | 4.6—18.1% | 4.2—44.2% | |
| Lease liabilities (non-current) | 0.3—0.8% | 0.3−55.7%0.8% | 0.2−64.3%1.3% | 0.4—1.4% | 0.5—2.6% | 0.6—2.3% | 0.7—7.2% | |
| Total liabilities | 6.4—19.5% | 6.4+22.3%19.5% | 5.4+10.1%29.1% | 5.7—22.1% | 4.9—27.0% | 5.2—20.3% | 4.9—51.4% | |
| Retained earnings | −178—−542% | −178—−542% | −170—−916% | −163—−627% | −156—−857% | −148—−578% | −140—−1470% | |
| Shareholders' equity | 26—80.5% | 26+29.0%80.5% | 13—70.9% | 20—77.9% | 13—73.0% | 20—79.7% | −139—−1456% | |
| Total liabilities and equity | 33—100% | 33+27.6%100% | 19+94.5%100% | 26—100% | 18—100% | 26—100% | 9.5—100% | |
| Shares outstanding | 54—— | 54+14.5%— | 50+1935%— | 50—— | 47—— | 47—— | 2.5—— | |
| Cash-flow statement | ||||||||
| Depreciation and amortization | 0.2—1.6% | 0.1+7.4%1.6% | 0.1+5.5%1.6% | 0.1—2.0% | 0.1*—1.4% | 0.1—1.5% | 0.1—1.7% | |
| Share-based compensation | 2.0—14.7% | 1.0+210%26.7% | 0.6+231%15.5% | 0.3—12.0% | 0.2*—5.0% | 0.3—8.7% | 0.2—5.1% | |
| Cash from operating activities | −29—−210% | −7.0*—−197% | −8.4*—−231% | −6.1—−217% | −7.7*—−196% | −5.7*—−160% | — | |
| Capital expenditure | −0.1—−0.6% | −0.0*—−0.6% | 0*—0.0% | −0.0—−1.7% | −0.0*—−0.2% | −0.0*—−0.3% | — | |
| Cash from investing activities | −0.1—−0.6% | −0.0*—−0.6% | 0*—0.0% | −0.0—−1.7% | −0.0*—−0.2% | −0.0*—−0.3% | — | |
| Cash from financing activities | 33—239% | 20*−11.8%554% | −0.4*—−12.2% | 14—500% | 0.0*—0.4% | 22*—633% | — | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What CapsoVision, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Services(total)$1 M6.8%+18%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Events at CapsoVision, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 4 · Material agreement 6 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementResults announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share saleResults announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
10 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Nov 2019 | $65 M | No. 10 | $50 to $250 million | 114 | equity | SEC |
| Aug 2018 | $6 M | No. 9 | $2 to $10 million | 11 | equity | SEC |
| Jan 2018 | $8 M | No. 8 | $2 to $10 million | 8 | equity | SEC |
| Mar 2016 | $5 M | No. 7 | $2 to $10 million | 9 | equity | SEC |
| Jan 2014 | $16 M | No. 6 | $10 to $50 million | 6 | equity | SEC |
| Oct 2012 | $4 M | No. 5 | $2 to $10 million | 4 | equity, options | SEC |
| Dec 2011 | $1 M | No. 4 | Under $2 million | 8 | equity | SEC |
| Jan 2011 | $3 M | No. 3 | $2 to $10 million | 14 | equity | SEC |
| Feb 2010 | $3 M | No. 2 | $2 to $10 million | 7 | equity | SEC |
| Jul 2009 | $1 M | No. 1 | Under $2 million | 4 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at CapsoVision, Inc.#
2 labor condition applications certified in fiscal 2025 for 2 positions, at a median wage of $105 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| QA/RA SpecialistBioengineers and Biomedical Engineers | 1 | $85 K |
| Software EngineerSoftware Developers | 1 | $125 K |
Where: Saratoga, CA 2
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 2 | 2 | $105 K | 2 |
| FY2024 | 5 | 5 | $85 K | 5 |
| FY2022 | 2 | 2 | $107 K | 2 |
| FY2021 | 1 | 1 | $62 K | 1 |
| FY2020 | 1 | 1 | $135 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as CapsoVision, Inc.
How CapsoVision, Inc. compares in Medical Devices
- Market cap$372 M · higher than 45% of 142
- Revenue$14 M · higher than 19% of 155
- Net margin-210.3% · higher than 6% of 144
- Revenue growth15.2% · higher than 60% of 104
- Price / sales26.8× · lower than 0% of 96
- Price / book28.1× · lower than 2% of 99
- FCF yield-6.2% · higher than 37% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| CapsoVision, Inc.🇺🇸 | $372 M | — | -210.3% | +15.2% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at CapsoVision, Inc.? Verify and update this profile — free
Show CapsoVision, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.